7145-49-5

Usage

Properties

1. Chemical Name: 3-Methoxy-5-nitrophenol
2. Appearance: Yellow crystalline
3. Solubility: Insoluble in water, soluble in organic solvents
4. Odor: Mild, sweet
5. Toxicity: Moderately toxic

Specific Content

1. Nitro group and methoxy group attached to a phenol ring
2. Commonly used as a starting material in the synthesis of pharmaceuticals and agrochemicals
3. Used in the manufacture of dyes, perfumes, and flavoring agents
4. Can cause irritation to the skin, eyes, and respiratory system upon contact or inhalation.

InChI:InChI=1/C7H7NO4/c1-12-7-3-5(8(10)11)2-6(9)4-7/h2-4,9H,1H3

Upstream product

• 16618-67-0 3-bromo-5-nitroanisole 
• 5350-56-1 4-amino-1-methoxy-3,5-dinitrobenzene 
• 5327-44-6 3,5-dinitroanisole 
• 99-35-4 1,3,5-trinitrobenzene 
• 586-10-7 3-methoxy-5-nitroaniline 

Downstream Products

• 1098619-23-8 3-[(3,5-dichlorophenyl)methoxy]-4-methoxyphenylamine 
• 1610450-57-1 tert-butyl (4-((2-((3-methoxy-5-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)phenyl)amino)-pyridin-4-yl)oxy)naphthalen-1-yl)carbamate 
• 1610450-58-2 4-((4-aminonaphthalen-1-yl)oxy)-N-(3-methoxy-5-(2-(2-(2-methoxyethoxy)ethoxy)-ethoxy)phenyl)pyridin-2-amine 

Relevant academic research and scientific papers

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

N-PHENYL-3-QUINAZOLIN-6-YL-BENZAMIDE DERIVATIVES AS P38 KINASE INHIBITORS

There are provided compounds of formula I, wherein R1A to R1E, R2, R3, R4A to R4C, L and X have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

UREA DERIVATIVES USEFUL AS KINASE INHIBITORS

There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

KINASE INHIBITORS

There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

UREA DERIVATIVES USEFUL AS KINASE INHIBITORS

There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

KINASE INHIBITORS BASED UPON N-ALKYL PYRAZOLES

There are provided compounds of formula (I), wherein R1 to R5, Ak and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

A convenient method of meta-directing nitration of 3-substituted phenol by lanthanide (III) nitrates

Thirteen compounds of 3-substituted phenols were nitrated by lanthanide(III) nitrates in a solution of ethyl acetate. Whether the substituents were ortho-, para-directing groups or meta-directing groups, only one kind nitrated product, 3-substituted-5-nitropenol, and its intermediate were obtained respectively.

Competing reactions leading to propene loss from the molecular ions of aryl n-propyl ethers

The mechanisms of the elimination of a propene molecule from the molecular ions of a series of 3- and 4-substituted aryl n-propyl ethers (YC6H4OC3H7, Y = H, CH3 CF3, NO2, CH3S and CH3O) were examined with the use of deuterium labelling and tandem mass spectrometry. Propene loss dominates in the ion-source reactions and is the exclusive process observed for the metastable molecular ions of most of the aryl n-propyl ethers. This process is concluded to proceed by two distinct pathways on the basis of the relative importances of the losses of C3H4D2 and C3H5D from the ionized ethers labelled with two deuterium atoms at the β-position of the n-propyl group in combination with the results of an analysis of the product ion structures. One pathway involves intermediate formation of an ion-neutral complex composed of a YC6H4O. radical and a +CH(CH3)2 carbenium ion. This complex reacts further by proton transfer prior to dissociation with the formation of product ions, which have the same structure as the corresponding ionized and substituted phenols, YC6H4OH+.. The second pathway involves a reversible 1,5-H shift from the β-position of the propyl group to the 2- or 6-position of the aromatic ring with the formation of a distonic ion, which expels propene to afford the molecular ion of a substituted cyclohexa-2,4-dienone species. The first pathway prevails for most of the ionized ethers with the exception of the molecular ions of the 3-methoxy- and 3-methylthio-substituted ethers, which expel propene largely by we second pathway. In addition, the 1,5-H shift-initiated propene loss is particularly pronounced:For the metastable molecular ions of these latter two ethers, suggesting that this reaction is associated with a lower critical energy than the reaction involving formation of an ion-neutral complex.